Proceedings.

IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc.

Follow
Active
Proceeding
Receivership (court-appointed)section 243(1) of the Bankruptcy and Insolvency Act
Court
Court of King's Bench of Alberta
File
2601-06780
Filings held9
Last activity11 Jun 2026
On the record157 days
Secured debt$12.2M
OverviewSummary updated

IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. were placed in court-appointed receivership on April 17, 2026, when the Court of King's Bench of Alberta appointed Alvarez & Marsal Canada Inc. receiver and manager on the application of Farm Credit Canada under section 243(1) of the Bankruptcy and Insolvency Act. On an estimated book value basis at that date the group carried total assets of $12,204,079 against total liabilities of $12,538,698. Farm Credit Canada holds the secured debt at $12,179,678; the largest unsecured claims are Business Development Bank of Canada at $133,400 and WPIC Marketing Limited at $81,171. The receivership is carried under court file no. 2601-06780.

Proceedings AIAsk this case — answers cite the filings
Ask in plain language. The answer comes only from this case’s filings, each one cited.
Enter to send · Shift+Enter for a new line
Case updates9 dated entries
#Report

The officer filed report no. First Report. The Receiver took control of IGY's property, terminated all employees effective May 1, 2026, and is pursuing a two-phase sale and investment solicitation process (SISP) to sell the business/property, with an alternative liquidation strategy available if no acceptable bids are received.

Source: First Report of the Receiver

#Order

Receivership order pronounced April 17, 2026 put Alvarez & Marsal Canada Inc. in as receiver and manager over the three IGY companies on Farm Credit Canada's application.

Source: Receivership Order

Parties

Debtor

IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc.

Receiver

Alvarez & Marsal

Capital structureAs asserted in the filings
stated amounts, drawn to scale
#Priority classCreditorAmountSource
4SecuredFarm Credit Canada · in 34 casesPer books and records as at April 17, 2026 (receivership date); preliminary list submitted by the Debtor without admission as to liabilities or privilege. — debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$12.2MNotice to Creditors
8UnsecuredBusiness Development Bank of Canada · in 241 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$133KNotice to Creditors
8UnsecuredWPIC Marketing LimitedAmount listed in $CAD per document header — debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$81.2KNotice to Creditors
8UnsecuredAccolade Consulting Group Inc.debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$26.7KNotice to Creditors
8Unsecured0413178 Condo Corpdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$25KNotice to Creditors
8UnsecuredRoyal Bank of Canada - VISAdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$15.8KNotice to Creditors
8UnsecuredDicentra · in 2 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$12.8KNotice to Creditors
8UnsecuredComfort Airedebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$7.89KNotice to Creditors
8UnsecuredK&L Gates LLPAmount listed in $CAD per document header — debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$6.58KNotice to Creditors
8UnsecuredEcoLab Co. · in 11 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$6.4KNotice to Creditors
8UnsecuredSeparator Technology Solutions US Inc.Amount listed in $CAD per document header — debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$6.03KNotice to Creditors
8UnsecuredMNP LLP · in 63 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$5.04KNotice to Creditors
8UnsecuredRock and Flower Inc.Amount listed in $CAD per document header — debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$4.44KNotice to Creditors
8UnsecuredCity of Airdrie - Utilitiesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$4.3KNotice to Creditors
8UnsecuredExercising Nutritionally, LLCAmount listed in $CAD per document header — debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$3.86KNotice to Creditors
8UnsecuredBona Fide Plumbing and Gasfitting Ltd. · in 2 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$3.25KNotice to Creditors
8UnsecuredVWR International Co · in 8 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$3.2KNotice to Creditors
8UnsecuredDirect Energy Business · in 8 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$3.05KNotice to Creditors
8UnsecuredCertified Laboratories · in 16 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$1.57KNotice to Creditors
8UnsecuredImpact Electric (1993) Ltd.debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$1.38KNotice to Creditors
8UnsecuredPeninsula Canada · in 2 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$1.17KNotice to Creditors
8UnsecuredXerox Canada Ltd. · in 72 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$1KNotice to Creditors
8UnsecuredQ&C Servicesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$969Notice to Creditors
8UnsecuredOrkin Canada Corporation · in 50 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$705Notice to Creditors
8UnsecuredCedarlane Labsdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$552Notice to Creditors
8UnsecuredCintas Canada Limited · in 87 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$493Notice to Creditors
8UnsecuredAirdrie Alarm and Surveillance Inc.debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$428Notice to Creditors
8UnsecuredCreospark Consulting Services Inc.debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$398Notice to Creditors
8UnsecuredFederal Express Canada Corporation · in 18 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$388Notice to Creditors
8UnsecuredRogers Communications Canada Inc. · in 12 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$333Notice to Creditors
8UnsecuredAir Liquide Canada Inc. · in 78 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$226Notice to Creditors
8UnsecuredCulligan Water · in 31 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$204Notice to Creditors
8UnsecuredUline Canada Corporation · in 71 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$172Notice to Creditors
8UnsecuredGunjot KhanujaIndividual creditor; address/location redacted in document — debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$77Notice to Creditors
8UnsecuredEvexla Biosciencedebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$60Notice to Creditors
8UnsecuredHoliday Inn Express Airdriedebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$1Notice to Creditors
8UnsecuredToyota Industries Commercial Finance Canada, Inc. · in 12 casesdebtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$1Notice to Creditors
8UnsecuredWorkers' Compensation Board - Alberta · in 14 casesRegulatory body claim, listed as ordinary unsecured amount owing per debtor's records — debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · as of 17 Apr 2026$1Notice to Creditors
Sale processAs stated in the filings

Sale process approved — The SISP is approved and the Receiver is authorized to implement it and enter into resulting agreements, subject to further Court approval of any transaction.Sales, Investment, and Solicitation Process Order · 11 Jun 2026

Bid deadline

17 July 2026

Sales, Investment, and Solicitation Process Order

Estate financialsReported figures — never derived
Total assets at filing$12.2M
Total liabilities at filing$12.5M

As at 17 Apr 2026 · per Estimated Book Value; Receiver has not audited, reviewed or otherwise attempted to verify the accuracy · Consolidated - IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. — Cash and accounts receivable balances as at April 17, 2026; PP&E and intangible assets as at December 31, 2024, stated as not materially different as at receivership date. Total liabilities figure is sum of secured ($12,179,678) and unsecured ($359,020) creditors as stated in document.

Cumulative receipts

$41.4K

As at 1 Jun 2026First Report of the Receiver

Cumulative disbursements

$221K

As at 1 Jun 2026First Report of the Receiver

Cash on hand

$221K

As at 1 Jun 2026First Report of the Receiver

Professional fees to date

$168K

As at 1 Jun 2026First Report of the Receiver

Documents
9 filings
DateDocumentFile
Application
  • Appointee role receiver and manager
  • Commencement date 17 April 2026
  • Court COURT OF KING’S BENCH OF ALBERTA
  • Court file no 2601-06780
PDF
Approval OrderPDF
Sales, Investment, and Solicitation Process Order
  • Bid deadline 17 July 2026
  • Order date 11 June 2026
  • Outside date 19 August 2026
  • Sale outcome Sale process approved — The SISP is approved and the Receiver is authorized to implement it and enter into resulting agreements, subject to further Court approval of any transaction.
PDF
First Report of the Receiver
  • Cash on hand $221K · Note: Ending cash balance per Interim Statement of Receipts and Disbursements · As at: 2026-05-29
  • Disbursements $221K · Note: Primarily payroll, professional fees and costs, contractor fees, utilities & insurance, GST payable, SG&A · Since: Receivership Date (April 17, 2026) to May 29, 2026
  • Financial position Assets $12.2M · Liabilities $12.5M · per Companies' books and records; estimated book value, unaudited - Receiver has not performed audit/review · entity - IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc., and IGY Life Sciences USA, Inc. (collectively) — As at the Receivership Date. Assets: Property, Plant, and Equipment $11,642,674; Intangible Assets $459,130; Cash and Cash Equivalents $60,000; Accounts Receivable $42,275. Liabilities: Secured creditors $12,179,678; Unsecured creditors $359,020. Realizable values may materially differ from estimated book value. Receiver has not undertaken a claims process for unsecured creditors and expresses no opinion on accuracy/completeness of creditor amounts.
  • Operational summary The Receiver took control of IGY's property, terminated all employees effective May 1, 2026, and is pursuing a two-phase sale and investment solicitation process (SISP) to sell the business/property, with an alternative liquidation strategy available if no acceptable bids are received.
  • + 5 more extracted facts
PDF
Service ListPDF
Notice to Creditors
  • Financial position Assets $12.2M · Liabilities $12.5M · as at 17 Apr 2026 · per Estimated Book Value; Receiver has not audited, reviewed or otherwise attempted to verify the accuracy · Consolidated - IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. — Cash and accounts receivable balances as at April 17, 2026; PP&E and intangible assets as at December 31, 2024, stated as not materially different as at receivership date. Total liabilities figure is sum of secured ($12,179,678) and unsecured ($359,020) creditors as stated in document.
  • Secured creditors $12.2M · Note: Per books and records as at April 17, 2026 (receivership date); preliminary list submitted by the Debtor without admission as to liabilities or privilege. · Page: 3 · As of: 2026-04-17 · Debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · Creditor: Farm Credit Canada
  • Unsecured creditors $172 · Page: 3 · As of: 2026-04-17 · Basis: Preliminary list of creditors as submitted by the Debtor without admission as to liabilities · Debtor: IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc. · Creditor: Uline Canada Corporation
PDF
Originating Application
  • Applicant FARM CREDIT CANADA
  • Appointee Alvarez & Marsal Canada Inc.
  • Appointee role receiver
  • Commencement date 15 April 2026
  • + 2 more extracted facts
PDF
Receivership Order
  • Applicant Farm Credit Canada
  • Appointee Alvarez & Marsal Canada Inc.
  • Appointee role receiver and manager
  • Commencement date 17 April 2026
  • + 3 more extracted facts
PDF
Affidavit of Dale SniderPDF

Filing titles, dates, and extracted key facts are public.

CiteProceedings., “IGY Immune Technologies & Life Sciences Inc., IGY Life Sciences Manufacturing Inc. and IGY Life Sciences USA, Inc.” (Receivership (court-appointed)), Court of King's Bench of Alberta. Retrieved 20 September 2026, https://proceedings.ca/case/igy-immune-technologies-life-sciences-inc-igy-life-sciences-manufacturing-inc-an

Recently updated

1281805 B.C. Ltd.

British Columbia · NOI

18 Sep 2026

Collection Tuff Avenue Inc.

Quebec · Bankruptcy

18 Sep 2026

6511 Sussex Heights Development Ltd. ("Highline Metrotown") and Minoru View Homes Ltd. ("Minoru Square") et al.

British Columbia · Receivership (court-appointed)

18 Sep 2026

177 Cross Argus Development Inc.

Ontario · NOI

18 Sep 2026

Sources last checked · summary updated 1 September 2026 · Report a correction · Printed from proceedings.ca/case/igy-immune-technologies-life-sciences-inc-igy-life-sciences-manufacturing-inc-an

Facts and summaries are extracted automatically from the court filings linked on each page; the filings remain the authoritative record. Suggested corrections are reviewed against the source filings.